NZ258684A - Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigen - Google Patents

Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigen

Info

Publication number
NZ258684A
NZ258684A NZ258684A NZ25868493A NZ258684A NZ 258684 A NZ258684 A NZ 258684A NZ 258684 A NZ258684 A NZ 258684A NZ 25868493 A NZ25868493 A NZ 25868493A NZ 258684 A NZ258684 A NZ 258684A
Authority
NZ
New Zealand
Prior art keywords
sequence
group
streptococcus
protein
seq
Prior art date
Application number
NZ258684A
Other languages
English (en)
Inventor
James L Michel
Dennis L Kasper
Frederick M Ausubel
Lawrence C Madoff
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Publication of NZ258684A publication Critical patent/NZ258684A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ258684A 1992-11-02 1993-11-02 Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigen NZ258684A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
NZ258684A true NZ258684A (en) 1997-04-24

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ258684A NZ258684A (en) 1992-11-02 1993-11-02 Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigen

Country Status (14)

Country Link
EP (1) EP0669985A1 (no)
JP (1) JPH08505282A (no)
KR (1) KR100349331B1 (no)
AU (1) AU689452B2 (no)
CA (1) CA2146926A1 (no)
FI (1) FI951979A (no)
HU (1) HU220198B (no)
IL (1) IL107458A0 (no)
NO (1) NO951629L (no)
NZ (1) NZ258684A (no)
PL (1) PL177302B1 (no)
RU (1) RU2209247C2 (no)
WO (1) WO1994010317A2 (no)
ZA (1) ZA938171B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
EP1100920A2 (en) * 1998-07-27 2001-05-23 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
BR9916473A (pt) * 1998-12-22 2002-01-15 Microscience Ltd Proteìnas de superfìcie exterior, seus genes e seu uso
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
GB9910375D0 (en) * 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
CA2424433A1 (en) 2000-10-13 2002-04-18 Shire Biochem Inc. Bvh-a2 and bvh-a3 antigens of group b streptococcus
WO2004080490A2 (en) 2003-03-07 2004-09-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
LT2144924T (lt) * 2007-04-16 2016-10-10 Minervax Aps Sulieto baltymo vakcina
PL2329020T3 (pl) 2008-08-28 2013-08-30 Novartis Ag Prezentacja izoform polipeptydu na powierzchni komórki poprzez nadczytywanie kodonu stop
US11325950B2 (en) 2015-10-21 2022-05-10 Minervax Aps Immunogenic fusion protein
US10888610B2 (en) 2015-12-30 2021-01-12 Minerv Ax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754000B2 (ja) * 1986-04-16 1998-05-20 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド 細菌抗原、抗体、ワクチン及びその製造方法
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein

Also Published As

Publication number Publication date
AU5665494A (en) 1994-05-24
WO1994010317A2 (en) 1994-05-11
HUT70981A (en) 1995-11-28
CA2146926A1 (en) 1994-05-11
JPH08505282A (ja) 1996-06-11
IL107458A0 (en) 1994-02-27
KR100349331B1 (ko) 2003-01-06
FI951979A (fi) 1995-06-29
KR950704492A (ko) 1995-11-20
FI951979A0 (fi) 1995-04-26
RU2209247C2 (ru) 2003-07-27
WO1994010317A3 (en) 1994-07-07
EP0669985A1 (en) 1995-09-06
AU689452B2 (en) 1998-04-02
NO951629L (no) 1995-07-03
HU220198B (hu) 2001-11-28
PL177302B1 (pl) 1999-10-29
NO951629D0 (no) 1995-04-28
ZA938171B (en) 1995-03-07
PL308555A1 (en) 1995-08-21

Similar Documents

Publication Publication Date Title
US6342223B1 (en) Immunogenic composition for group B Streptococcus
AU689452B2 (en) Conjugate vaccine against group B streptococcus
EP0571538B1 (en) Structural gene of pneumococcal protein
US6426074B1 (en) Group B Streptococcus vaccine
AU693175B2 (en) Epitopic regions of pneumococcal surface protein A
EP0491865B1 (en) Conjugate vaccine for group b streptococcus
PL186847B1 (pl) Konstrukcja DNA, wektor ekspresyjny, gospodarz, białko fuzyjne i sposób przygotowania bakterii
AU722078B2 (en) Conjugate vaccine against group B Streptococcus

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)